Is Nektar Therapeutics (NKTR) overvalued? · rev $98.4M
Nektar Therapeutics (NKTR) is a biotechnology company listed on US.
This page asks whether Nektar Therapeutics (NKTR) looks expensive on cached numbers — not a short thesis.
Latest reported NKTR revenue for 2024-12-31 was $98.4M. Net income was -$119.0M. Revenue was up 9.2% from 2023-12-31 to 2024-12-31. NKTR currently screens at market cap $307.2M.
NKTR currently screens at market cap $307.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next NKTR 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the NKTR stock page for the full model, not this heading.
Not investment advice.